Informed Decision-Making in HR+ Breast Cancer
Kevin Kalinsky, MD, MS, of Emory Winship Cancer Institute, discusses treatment options for HR-positive/HER2-negative breast cancer and comments on the evolving role of genomic testing in regard to treatment selection.
CancerNetw_HRBreast_CC_Kal_Seg01_Advances
Video Player is loading.
Recent Videos
Diagnosis and Management of mCSPC
The Oncotype DX Breast Recurrence Score for HR+ Breast Cancer
Genomic Testing vs Genetic Testing for HR+ Breast Cancer
Genomic Assays and Adjuvant Therapy for HR+ Breast Cancer
Neoadjuvant Therapy for HR+ Breast Cancer
NCCN Guidance on Gene Profiling in Early-Stage HR+ Breast Cancer
Gene Profile-Directed Therapy for Early-Stage HR+ Breast Cancer
The Oncotype DX Breast Recurrence Score: Clinical Trial Data
Role of Gene Profiling Assays in Early-Stage HR+ Breast Cancer
Perioperative Decision-Making in HR+ Breast Cancer
Related Content
Treatment Options in Metastatic Castration-Sensitive Prostate Cancer
March 13th 2022Article
In this program Atish D. Choudhury, MD, PhD, discusses recent updates on long-term safety and efficacy data in patients with metastatic castration-sensitive prostate cancer and the importance of patient communication and quality of life while on treatment.
